Spatial transcriptomics helps researchers see where genes are active in tissue. The Xenium In Situ platform is one of the leading tools used for high-plex, single-cell spatial profiling. As more labs offer Xenium services, picking the right provider matters more than ever. Certification is just the starting point, not the whole story Xenium certification means […]
The post What to Look for in a Xenium Certified Service Provider for Spatial Transcriptomics Studies appeared first on Medical News Bulletin.
When people talk about trauma, you’ll usually hear them mention broken bones, deep cuts, burns, bruises, etc. And that’s indeed all trauma, but in medical terms, ‘trauma’ is broader. To keep things simple, any sudden and intense physical stress to your body is considered trauma. And it doesn’t matter whether you get it in a […]
The post How Inflammation After Trauma Can Affect the Entire Body appeared first on Medical News Bulletin.
The White House did not nominate a new CDC director on Wednesday despite coming up against a federally imposed deadline to do so.
White House spokesperson Kush Desai told Healio that NIH Director Jay Bhattacharya, MD, PhD, will continue to perform the duties of acting CDC director until a permanent replacement is selected.
“Restoring competence and confidence in CDC decision-making remains a top priority for the White House after the Biden administration’s COVID excesses,” Desai said. “Dr. Jay Bhattacharya’s leadership at the CDC is a great service to the country, and he has now been delegated
The FDA has given accelerated approval to Avlayah as a treatment for neurologic manifestations of Hunter syndrome, also known as mucopolysaccharidosis type II, according to a press release from Denali Therapeutics.
The drug is approved for this treatment indication “when the medication is started in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment,” the FDA said in a release.
Avlayah (tividenofusp alfa-eknm, Denali Therapeutics), an enzyme replacement therapy, is the first treatment approved for this patient population in nearly 20
NEW ORLEANS — Bridge-enhanced ACL repair may have significantly higher failure rates at minimum 1-year follow-up vs. ACL reconstruction, according to results presented here.
“[Despite] the enthusiasm for the [bridge-enhanced ACL repair (BEAR), Miach Orthopaedics] implant and the utilization of it as a means to avoid a typical reconstruction, which we know long term has had excellent outcomes, we may be a little more tempered in terms of proceeding with the BEAR on everyone,” Laith M. Jazrawi, MD, FAAOS, chief of sports medicine at NYU Langone Health, told Healio about results
In patients with glaucoma, visual field loss has no clear link to difficulties in low-light environments until the loss passes a certain threshold, according to a study published in Ophthalmology Glaucoma.
“The majority of assessments of vision-related quality of life among people with glaucoma have placed little emphasis on the experience and performance of tasks conducted in low-light conditions,” Maanasi Mahalingam, MOptom, of the University of Western Australia, and colleagues wrote. “As a result, the impact of glaucoma on activities performed under low luminance is
More than half of patients with breast cancer who receive chemotherapy may experience moderate to very severe neuropathy more than 5 years after their treatment.
A survey of nearly 1,500 breast cancer survivors revealed more than 60% treated with chemotherapy experienced long-term neuropathy compared with 36% not treated with chemotherapy.
Taxane chemotherapy exacerbated the issue, as individuals who received those drugs had three times the odds of reporting neuropathy than those who did not undergo chemotherapy.
“It’s really important for clinicians to realize that the majority of older
The FDA has approved the first selective glucocorticoid receptor antagonist therapy for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancers whose disease has progressed after prior therapy.
Relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) received approval for patients who have received up to three prior systemic treatment regimens, including bevacizumab (Avastin, Genentech).
The FDA based its decision on the randomized phase 3 ROSELLA trial, which showed a 30% improvement in PFS and 35% improvement in